Phase II study of TAS-114 in combination with S-1 in patients with advanced gastric cancer refractory to prior chemotherpy.
Phase of Trial: Phase II
Latest Information Update: 10 Jan 2019
At a glance
- Drugs TAS 114 (Primary) ; Gimeracil/oteracil/tegafur
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms TAS114_GC study
- 07 Jan 2019 According to UMIN, the anticipated date for data entry closure is 31 Jan 2019, and the date for conclusion of data analysis is 1 May 2020.
- 07 Jan 2019 Status changed from suspended to completed.
- 19 Sep 2018 Status changed from recruiting to suspended.